Naltrexone improves blood glucose control in type 1 diabetic women with severe and chronic eating disorders.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Diabetes Care

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIACARE.27.3.847PMID 14988322
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Disordered eating behavior and microvascular complications in young women with insulin-dependent diabetes mellitus.

  1997cited by this paper
• A detailed longitudinal analysis on the use of naltrexone in the treatment of bulimia.

  1995cited by this paper
• Insulin Omission in Women With IDDM

  1994cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Eating Disorders and IDDM: A problematic association

  1992cited by this paper

• Dopamine in the Regulation of Glucose Homeostasis, Pathogenesis of Type 2 Diabetes, and Chronic Conditions of Impaired Dopamine Activity/Metabolism: Implication for Pathophysiological and Therapeutic Purposes

  2023cites this paper
• Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine

  2022cites this paper
• Effects of genotype and food on naltrexone exposure in adolescents

  2022cites this paper
• BINGE EATING DISORDERS; UPDATED AND EMERGING APPROACHES

  2021cites this paper
• Developmental Considerations for the Use of Naltrexone in Children and Adolescents.

  2021cites this paper
• Pharmacological therapies to address obesity in type 1 diabetes.

  2020cites this paper
• Medication for Binge Eating

  2020cites this paper
• Binge Eating: A Transdiagnostic Psychopathology

  2020cites this paper
• Naltrexone Reduces Binge Eating and Purging in Adolescents in an Eating Disorder Program

  2019cites this paper
• Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa

  2018cites this paper
• Hormonal and neural mechanisms of food reward, eating behaviour and obesity

  2014cites this paper
• A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder.

  2013cites this paper
• Predictors of diabetes mellitus and abnormal blood glucose in patients receiving opioid maintenance treatment.

  2013cites this paper
• Current pharmacotherapy options for bulimia nervosa and binge eating disorder

  2012cites this paper
• Pharmacological management of binge eating disorder: current and emerging treatment options

  2012cites this paper
• From taste hedonics to motivational drive: central μ-opioid receptors and binge-eating behaviour.

  2009cites this paper
• Blood glucose level, alcohol heavy drinking, and alcohol craving during treatment for alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study.

  2009cites this paper
• Overview of Agents with Efficacy in Binge Eating

  2006cites this paper
• The hypothalamus-pituitary-ovary axis and type 1 diabetes mellitus: a mini review.

  2006cites this paper
• Role of opiates and their receptors in the regulation of food intake and body weight

  2005cites this paper